Background: Peripheral arterial disease is common and is associated with significant morbidity and mortality. Methods: We conducted a systematic review to identify randomized trials and systematic reviews of patients with intermittent claudication to evaluate surgery, endovascular therapy, and exercise therapy. Outcomes of interest were death, amputation, walking distance, quality of life, measures of blood flow, and cost. Results: We included eight systematic reviews and 12 trials enrolling 1548 patients. Data on mortality and amputation and on cost-effectiveness were sparse. Compared with medical management, each of the three treatments (surgery, endovascular therapy, and exercise therapy) was associated with improved walking distance, claudication symptoms, and quality of life (high-quality evidence). Evidence supporting superiority of one of the three approaches was limited. However, blood flow parameters improved faster and better with both forms of revascularization compared with exercise or medical management (low-to moderate-quality evidence). Compared with endovascular therapy, open surgery may be associated with longer length of hospital stay and higher complication rate but resulted in more durable patency (moderate-quality evidence). Conclusions: In patients with claudication, open surgery, endovascular therapy, and exercise therapy were superior to medical management in terms of walking distance and claudication. Choice of therapy should rely on patients' values and preferences, clinical context, and availability of operative expertise. (J Vasc Surg 2015;61:54S-73S.)
Peripheral arterial disease (PAD) remains a serious public health issue in the population older than 40 years in the United States. 1 After the flow-limiting atherosclerotic plaque is established, claudication impairs walking distance and quality of life. Current care includes lifestyle modification (exercise 2 and smoking cessation 3 ), medical therapy (antiplatelet agents such as aspirin or clopidogrel, cilostazol, lipid-lowering drugs, and adequate blood pressure control), and revascularization (surgical or endovascular). In addition to their potential impact on outcomes in patients with PAD, lifestyle interventions and medical treatments are also recommended as they can effectively reduce cardiovascular morbidity and mortality in at-risk patients.
The relative effectiveness of the available treatments for patients with intermittent claudication (IC), such as exercise therapy and revascularization (either by surgical bypass or endovascular interventions), is not well established. Studies of supervised exercise for people with IC have yielded inconsistent results. 2, 4, 5 Revascularization treats hemodynamically significant arterial lesions, increasing the blood flow to distal segments that are underperfused and improving pain-free walking distance. Endovascular therapy has evolved during the past 20 years, gaining popularity as a safe, minimally invasive, and feasible option. 6 Early promising results of endovascular interventions compared with exercise therapy have been questioned by randomized trials showing lower durability and increased costs with endovascular procedures. [7] [8] [9] Conversely, surgical bypass in people with claudication leads to immediate and sustained improvement with higher success rates compared with exercise therapy but with greater morbidity and mortality. 5 Last, although claudication is often caused by multilevel arterial occlusive disease of the lower extremity, 10 worse outcomes have been reported for endovascular interventions performed in the femoropopliteal region than in the aortoiliac segment. 11 The Society for Vascular Surgery (SVS) and its member surgeons have been major advocates of promoting prevention and treatment strategies for PAD. In this endeavor, a committee of experts in PAD treatment commissioned the conduct of this systematic review to evaluate the available modalities and their efficacy for the treatment of patients with claudication. This study will aid in the development of clinical practice guidelines METHODS This systematic review is conducted following recommendations from the Cochrane Collaboration 12 and is reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 13 The lower extremity revascularization committee of the SVS approved the protocol of this review.
Study eligibility. Studies were eligible for this review if they were (1) randomized trials or systematic reviews;
(2) enrolled patients with claudication (ie, symptomatic patients with peripheral vascular disease who had exertional pain with walking); (3) evaluated open bypass, endovascular revascularization, or exercise therapy; and (4) measured the outcomes of interest. Trials exclusively enrolling patients with critical limb ischemia (CLI), defined as rest pain or tissue loss, were excluded. For each comparison of interest, evidence was derived from a credible systematic review if it existed; if not, individual studies were evaluated.
The primary outcomes of interest were mortality, amputation, and quality of life, which are patientimportant outcomes 14 and are considered to be critical and most relevant for the development of clinical practice guidelines. These outcomes are rare in claudicants, however; therefore, we included other outcomes, such as walking distance, measures of flow (ie, ankle-brachial index [ABI]), patency, cost, and health care utilization data.
Search strategy. Exploratory search revealed six existing well-conducted published systematic reviews that searched multiple electronic bibliographic databases between 2005 and 2011. Watson et al 15 Data extraction and analysis. Teams of reviewers working in duplicates reviewed abstracts and full-text articles and extracted descriptive, methodologic quality, and outcome data. Article review and data extraction were done using online systematic review software (DistillerSR, Ottawa, Ontario, Canada). Online electronic data extraction forms were piloted, then used. Chance-adjusted interreviewer agreement averaged 0.80.
Mixed treatment meta-analysis was planned but was later deemed not feasible because of the small number of trials included in each comparison in addition to the heterogeneity of trial populations. Descriptive narrative of the results is presented. Continuous variables were reported as mean, median, and standard-deviation, and categorical variables were reported as percentages.
RESULTS
The original search in 2011 identified 853 references and the update in 2014 identified 207 additional ones. We excluded 1041 citations for being duplicates of included studies, having no original data, or having an irrelevant population (majority of patients with CLI).
After screening abstracts and full-text references, we finally included 8 systematic reviews (3 Cochrane systematic reviews of randomized trials on exercise therapy, [21] [22] [23] 2 systematic reviews that compared supervised exercise with endovascular therapy, 24, 25 and 3 systematic reviews of nonrandomized surgical case series [26] [27] [28] ) and 12 trials evaluating endovascular or open surgical approaches.
The characteristics of the included trials are described in Table I , and the quality of these trials is described in Table II . Overall, the quality was fair (about 50% of the trials concealed allocation, loss to follow-up varied from 0% to 13% with a median of 6%, and with no significant imbalances at baseline in most studies). There was no study that was stopped early for benefit, an action that is usually associated with large effect sizes. 29 The included trials enrolled a total of 1548 patients with a median sample size of 84 (range, 36-264). The average age was 65 years, 70% of patients were males, 18% had diabetes, and 67% had history of smoking. The median length of follow-up was 15 months (range, 6-84).
Mortality and amputation events were rare. Overall death rate was 4% in the control groups, 6% in the supervised exercise groups, 23% in the angioplasty groups, and 22% in the surgery groups. The majority of death rates reported were based on either 1-or 2-year follow-up data, and only one study reported mortality rate obtained throughout a 6-year period. Two studies reported amputation rates in patients with claudication. Wolf et al 30 found amputation rate at 30-day follow-up to be 1% (2 of 133) and 0% (0 of 130) in patients who underwent percutaneous transluminal angioplasty (PTA) and surgery, respectively. Gelin et al, 5 analyzing 1-year follow-up data on 264 patients, reported 2% (2 of 89), 1% (1 of 89), and 0% (0 of 88) amputation rate for control, surgery, and exercise treatment groups, respectively.
The small size of the trials indicates that randomization has likely failed to achieve prognostic balance between the two study arms. Comparative effectiveness inference is quite limited. Low mortality rate, scarce long-term follow-up data, and different medical treatment regimens used in the included literature make inferences difficult as to whether medical treatment or exercise plus medical treatment decreases long-term mortality rates. Thus, mortality in patients with claudication is likely related to cardiovascular events and not necessarily attributable to the interventions. 31 Table III summarizes the rates and follow-up intervals of these events across trial arms.
The Fig depicts a summary of the results of this systematic review with the quality of evidence for each comparison. A narrative with the rationale for these results is presented thereafter. 
Exercise therapy
We identified three Cochrane systematic reviews 21-23 that evaluated the effect of exercise programs in patients with IC. The first review compared exercise programs with placebo or usual care and demonstrated high-quality evidence supporting benefit of exercise on walking performance parameters. However, data on amputation and mortality were limited because these events are rare in claudicants and there was no effect on ABI. 21 Similarly, the second review compared supervised exercise therapy with unsupervised exercise and showed high-quality evidence favoring supervised exercise on walking performance. 23 Table IV presents the details of these two reviews that summarized 36 trials. A third systematic review attempted to answer the question of which mode of supervised exercise is most effective. However, data comparing cycling, strength training, and upper arm ergometry were very imprecise (only 136 patients enrolled in 5 trials). 22 
Revascularization
Randomized controlled trials (RCTs) comparing surgery with medical management or exercise. Lundgren et al 32 demonstrated that maximum and symptomfree walking distances improved the most in patients randomized to surgery with an added physical training program, then in patients receiving surgery alone, then in the exercise-alone group. ABI and hallux pressure improved significantly in patients randomized to surgery with an added physical training program or to surgery alone, but not in the exercise-alone group.
RCTs comparing endovascular approaches with medical management or exercise. Creasy et al 33 showed that exercise therapy compared with PTA led to better mean claudicating distance. The PTA group had initial improvement in this distance at 3 months without subsequent improvement, whereas the exercise group had progressive improvements through a follow-up of 15 months. The PTA group had higher mean ABI. The MIMIC trial (adjuvant benefit of angioplasty in patients with mild to moderate IC) 34 compared PTA vs no PTA in patients already receiving supervised exercise and best medical therapy and followed them up for 24 months. The PTA group had higher adjusted absolute walking distance and ABI but not quality of life.
Nylaende et al 6 showed that early intervention with PTA and medical management seems to be superior to medical management alone in terms of improvements in the minimal and pain-free walking distances and perception of pain in the patients' primary symptomatic leg just before they had to stop when walking as measured by a visual analog scale. PTA and medical management seemed also to be superior to medical management alone in terms of improvements in the quality of life. The greatest difference between the groups was obtained after 3 months in the 36-Item Short Form Health Survey (SF-36) domains of physical functioning, bodily pain, and reported health transition. Only with regard to physical functioning did this positive effect last for 2 years. Results from the Claudication Scale (CLAU-S) form showed superiority of the combined approach in the two domains of pain during activity and pain severity. This difference, however, was noted only at 3 and 12 months but not after 2 years, when no differences between groups were observed. The PTA group had more improvements in the ABI up to 2 years of follow-up.
Hobbs at al 35 demonstrated that PTA was superior to supervised exercise and best medical treatment on the basis of significant improvement in mean ABI and both initial claudication distance and absolute claudication distance at 6 months of follow-up.
Perkins et al 36 showed early superiority of an exercise training program over PTA on claudication and maximum walking distances; however, at long-term follow-up, there was no significant difference between the groups. PTA led to constant increases of ABI, whereas an exercise training program did not.
Spronk et al 7, 8 compared endovascular revascularization with a hospital-based exercise program. The two groups had similar and statistically significant improvements in maximum and pain-free walking distances. After follow-up, there were no significant differences in the adjusted 6-and 12-month EuroQol, rating scale, and SF-36 physical functioning values. The two groups had similar improvements in ABI at rest and with exercise; however, the endovascular approach had somewhat more immediate improvement. Seven-year follow-up also showed similar functional performance and quality of life between the two groups. 37 Whyman et al 9 demonstrated that after 2 years of follow-up, the addition of PTA to medical treatment (aspirin, advice on smoking cessation and exercise) did not result in a significant difference in patient-reported maximum walking, treadmill onset to claudication, treadmill maximum walking distances, ABI, or any of the items of the Nottingham Health Profile score.
The CLEVER trial (Claudication: Exercise vs Endoluminal Revascularization) randomized patients to supervised exercise, OMC, and stent treatment. All patients received cilostazol 100 mg twice daily during the study period. At 6 months, the peak walking time was much improved in the supervised exercise group compared with both the OMC-alone group (eg, risk factor management, use of antiplatelet therapy, and use of claudication pharmacotherapy) and the stent treatment group (mean change vs baseline, 5.8 6 4.6, 3.7 6 4.9, and 1.2 6 2.6 minutes, respectively; P < .001 for the comparison of supervised exercise vs OMC, P < .02 for stent treatment vs OMC, and P < .04 for supervised exercise vs stent treatment). 20 After 6 months of follow-up, the CLEVER study, using two dedicated claudication questionnaires, the Walking Impairment Questionnaire and the Peripheral Artery Questionnaire, showed that the stent revascularization group had better patient-reported quality of life compared with the supervised exercise and OMC groups. 20 As the CLEVER trial was not designed to address the reasons for better pain severity, walking speed scores, and less physical limitation and overall quality of life in the stent treatment group, further investigation of long-term results was recommended by the CLEVER study investigators. 20 There was no significant improvement of baseline ABI compared with 6-month follow-up in either the OMC or supervised exercise treatment group; however, resting ABI improved by 0.29 6 0.33 in the stenting revascularization group (P < .0001). 20 Results presented from a recent trial of 212 claudicants compared endovascular revascularization combined with supervised exercise to exercise alone. After 12 months, the combination therapy resulted in significant greater improvements in pain-free and maximum walking distance and health-related quality of life scores. 38 Two systematic reviews of the randomized trials that compared endovascular therapies with supervised exercise therapy concluded that they are likely equal and that the combination of both is likely better than either approach in terms of improving walking distance and some domains of the quality of life scales. 24, 25 RCTs comparing endovascular approaches with open surgery. van der Zaag et al 39 showed that bypass had higher clinical improvement on the Rutherford classification than PTA (53% of patients improved vs 33%, an absolute difference of clinical success of 20%; 95% confidence interval [CI], 26%-46%). Bypass also had higher cumulative 1-year primary patency (82%) compared with PTA (43%) and less incidence of a reocclusion (hazard ratio for PTA, 2.24; 95% CI, 0.9-5.58).
Wolf et al 30 compared surgery with PTA. Patients in both treatment groups had improvement in functional status measured by the Sickness Impact Profile, although no difference was demonstrated according to treatment received.
Two systematic reviews add evidence to the comparison between open surgery and endovascular therapy, although they included patients with CLI. A systematic review and meta-analysis evaluated the clinical outcomes of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac occlusive disease. Comparisons of these nonrandomized surgical series showed that open bypass had longer hospital stay (13 days vs 4 days; ABI, Ankle-brachial index; CI, confidence interval; MD, mean difference; RCTs, randomized controlled trials.
JOURNAL OF VASCULAR SURGERY P < .001) and higher complications rate (18.0% vs 13.4%; P < .001) and 30-day mortality (2.6% vs 0.7%; P < .001). Patency and durability of bypass were superior, however. 26 A second systematic review compared open surgical and percutaneous transluminal methods for the treatment of femoropopliteal arterial disease and showed that open surgery was associated with higher 30-day morbidity but no difference in 30-day mortality. Higher primary patency in the surgical treatment arm was also found. 28 RCTs comparing any revascularization with medical management or exercise. Gelin et al 5, 40 demonstrated that invasive revascularization (open surgical or endovascular procedures) increased walking capacity (treadmill exercise power and maximum treadmill walking distance) and was more effective than supervised training in alleviating illnessspecific symptoms and improving certain aspects of physical functioning, the primary health-related quality of life domains affected by claudication. However, the treatment effect sizes were modest, and untreated claudicants reported at most small deterioration in health-related quality of life. Invasive revascularization increased leg blood pressure and flow parameters (maximum postischemic calf blood flow after treadmill exercise, hallux systolic pressure, and ABI).
Similarly, a recent trial of 158 patients randomized patients to an invasive strategy (open repair for Trans-Atlantic Inter-Society Consensus [TASC] II D lesions and endovascular intervention for the aortoiliac and femoropopliteal TASC II A-C lesions) vs noninvasive strategy (education, exercise encouragement, cilostazol, and statins). Compared with the noninvasive group, the invasive group had better SF-36 physical component summary and two of its physical subscales, overall Vascular Quality of Life questionnaire score and three of five domain scores, and IC distance (þ124 m vs þ50 m; P ¼ .003) but not maximum walking distance. 41 Aortoiliac vs femoropopliteal disease in patients with claudication. Perkins et al 36 compared PTA with supervised exercise and found that patients with femoropopliteal disease and no aortoiliac involvement had improvement in the claudication distance at 6, 9, 12, and 15 months of follow-up after treatment with supervised exercise. In comparison, patients with aortoiliac disease with or without femoropopliteal disease failed to improve after either treatment.
The MIMIC trial 34 stratified patients by anatomic location and showed that PTA added to supervised exercise and best medical therapy was associated with increased adjusted absolute walking distance in patients with femoropopliteal disease (38% greater; 95% CI, 1-90) and in patients with aortoiliac disease (78% greater; 95% CI, 0-216).
Wolf et al 30 showed that patients with iliac disease fared better than those with femoropopliteal disease in terms of limb survival and primary patency, although no difference was demonstrated according to treatment received (surgery vs PTA). Patency rates for both PTA and surgery were reduced in the femoropopliteal segment compared with the same treatment applied to the aortoiliac segment.
A trial of 178 patients with IC due to femoropopliteal arterial disease compared angioplasty, a supervised exercise program, and combined treatment. The trial demonstrated that all three treatments were equally effective in improving walking distance and quality of life after 12 months. 42 Because data from RCTs regarding the relative efficacy of the different PAD treatments stratified by the anatomic location of the disease were sparse, meta-analyses of nonrandomized case series are included.
Aortoiliac occlusive disease. Endovascular vs open surgery for aortoiliac occlusive disease was compared in a meta-analysis of mostly nonrandomized series, 26 and most of these studies included patients with CLI. The open bypass groups experienced more complications and greater 30-day mortality. At 1, 3, and 5 years, primary patency rates were greater in the open bypass group. In extensive aortoiliac occlusive disease, meta-analysis of nonrandomized series 27 showed that with an endovascular approach, mortality ranged from 1.2% to 6.7%, and complications ranged from 3% to 45%. Clinical symptoms improved in 83% to100%. Technical success was achieved in 86% to 100% of the patients. The 4-or 5-year primary and secondary patency rates ranged from 60% to 86% and 80% to 98%, respectively.
Femoropopliteal occlusive disease. A systematic review summarized four RCTs and six observational studies reporting on a total of 2817 patients with femoropopliteal arterial disease (includes CLI patients). 28 Endovascular treatment was associated with lower 30-day morbidity (odds ratio [OR], 2.93; 95% CI, 1.34-6.41) and higher technical failure (OR, 0.10; 95% CI, 0.05-0.22) than bypass surgery. No difference was noted in 30-day mortality (OR, 0.92; 95% CI, 0.55-1.51). Higher primary patency in the surgical treatment arm was found at 1 year (OR, 2.42; 95% CI, 1.37-4.28), 2 years (OR, 2.03; 95% CI, 1.20-3.45), and 3 years (OR, 1.48; 95% CI, 1.12-1.97) of intervention.
Progression to amputation was found to occur more commonly in the endovascular group at the end of the second year (OR, 0.60; 95% CI, 0.42-0.86) and third year (OR, 0.55; 95% CI, 0.39-0.77) of intervention. Higher amputation-free (OR, 1.31; 95% CI, 1.07-1.61) and overall survival (OR, 1.29; 95% CI, 1.04-1.61) rates were found in the bypass group at 4 years.
Cost and utilization data
There is a paucity of data on cost analysis of treatments of IC. Three of four RCTs that were excluded from analysis because of inclusion of patients with CLI or mixing of claudication and CLI reported cost analysis. [43] [44] [45] A single-center Dutch RCT discussed the cost in patients with claudication treated by either endovascular revascularization or supervised exercise. 7 In this trial, Spronk et al 7 demonstrated that endovascular revascularization had higher total mean cumulative costs per patient compared with a hospital-based exercise program (mean difference, V2318; 99% CI, V2130-V 2506; P < .001). 7 The gain in total mean quality-adjusted life-years accumulated during 12 months, adjusted for baseline values, was not statistically different between the two groups. The follow-up costs are provided, showing that endovascular treatment carried significantly higher expenses compared with an exercise program; however, it is not reported whether it is related exclusively to a higher reintervention rate in the endovascular group. Nonetheless, in all instances, endovascular revascularization was more expensive compared with hospital-based exercise but with similar clinical outcomes at 12-month follow-up. It is also important to realize the differences in billing and reimbursement systems in Europe, which were assessed in this study, from those in the United States.
One cost-effectiveness study showed that compared with unsupervised exercise, supervised exercise was cost-effective in >75% of model simulations, with an incremental cost-effectiveness ratio of 711 to 1608 per quality-adjusted life-year gained. 46 Another economic analysis of patients with IC due to femoropopliteal arterial disease suggested that supervised exercise is more costeffective than angioplasty and that the combination of the two treatments is also more cost-effective than angioplasty alone. 47 On the basis of the concept of supervised exercise as the most cost-effective first-line treatment for IC, a cost analysis using a large Dutch health care insurance company database of 4954 patients was performed to evaluate the impact of a stepped care claudication treatment approach. 48 Three groups were created, supervised exercise, intervention, and no treatment group, aiming to identify the related costs to supervised exercise and intervention and how many patients would eventually need intervention after being enrolled in a supervised exercise program. The authors also computed the financial burden of reinterventions added to each patient's follow-up costs.
The main conclusion of this cost-analysis study suggested that supervised exercise must be always attempted as a first-line IC treatment before any intervention is performed to save thousands of Euros spent in perhaps unnecessary interventions. Several variables play a role in whether an intervention should be pursued first instead of a long exercise program. The study did not clearly state the severity of claudication (breakdown in Fontaine IIa and IIb not provided) and stratification of PAD extent and its impact on the treatment decision-making process (aortoiliac, femoropopliteal, or crural involvement or a combination of all three levels). Open and endovascular interventions overlap throughout the study regardless of their magnitude and were bundled together in a single "intervention" group for calculation purposes, which by itself is not ideal from a clinical (ie, complications, durability) or cost-savings perspective (ie, hospital stay, rehabilitation costs). Most important, the study did not explore the reasons (ie, age, work, daily physical and recreational activities) that some patients decided to initially proceed with a long supervised exercise program or for how long it would be tolerable instead of having first an intervention to quickly improve their clinical limitations (work and leisure activities) and quality of life. 48 
DISCUSSION
We conducted a systematic review to evaluate the relative efficacy of surgery, endovascular therapy, and exercise therapy. Data regarding patient-important outcomes (mortality, amputation, and quality of life) were sparse, limiting inference. The three treatments appear to be superior to medical management in terms of walking distance, pain, and claudication. The quality of such evidence is high. Blood flow parameters (eg, ABI) improve faster and better with both forms of revascularization compared with nonsurgical management with exercise or medical management; this improvement, however, may not necessarily correlate with clinical and patient-important improvement. Evidence supporting superiority of one of the three approaches is limited, although it seemed that the combination of supervised exercise therapy and invasive revascularization may be superior to exercise alone. A network meta-analysis 49 similarly concluded that the three active treatments are more effective than medical management, with limited comparative evidence between the three.
Data on cost-effectiveness and utilization in IC were minimal. This conclusion is similar to a systematic review commissioned by the SVS that evaluated the economicbased literature with respect to open and endovascular treatment of PAD. 50 A summary of 3 model-based, 12 cost-consequence, and 4 cost analyses suggested a trend favoring initial cost savings with endovascular therapy. Whether this benefit is sustained over time is unknown. Cost-efficacy inferences cannot be drawn from the existing literature because of a noted lack of standardized patientcentric outcomes, longitudinal data, and reintervention data. The available economic analyses emphasized the significant cost-effectiveness of supervised exercise therapy.
We attempted to compare intervention efficacy on the basis of anatomic location. Limited evidence suggests that patients with isolated iliac or femoropopliteal occlusive disease compared with those with combined iliac and femoropopliteal disease fare better in terms of symptom relief and improvement in walking distance, regardless of the type of intervention (supervised exercise, PTA, or surgical bypass). Because a hemodynamically acceptable inflow is deemed mandatory for infrainguinal repair, many trials aimed only to assess interventions in the femoropopliteal segment and purposely excluded patients with significant aortoiliac disease. Studies also did not stratify outcomes on the basis of the anatomic level of the disease, probably because of their small sample size.
The limitations of this report mainly relate to the small body of literature and a small number of trials that do not allow stratification according to prognostic factors and patient characteristics. Knowing the relative efficacy of interventions in various subgroups of patients is important for decision-making. Methodologic limitations of the included trials, imprecision (small numbers of patients and events leading to wide CIs), and inconsistency across studies affected our ability to draw inferences. 51 Dependence on surrogate outcomes is another challenge in the field because hard end points (mortality and amputations) are rare in claudicants. New modalities of surrogate measurement, such as the response of the endothelium to exercise in patients with claudication (eg, the brachial artery flowmediated dilation), are being developed and tested. 52 Practice and research implications. This study demonstrates that compared with medical management alone, interventions such as supervised exercise, endovascular interventions, or surgical bypass result in improvement in claudication symptoms, walking distance, and quality of life in most patients. Unfortunately, endovascular interventions and surgical bypass come at a significant expense, can have limited durability, and may be associated with morbidity and mortality. Data on which intervention is best suited for a particular patient to obtain the best outcome are lacking. Therefore, patients should be informed of the current uncertainty and the pros and cons of these treatments. Patients' values and preferences and availability of operative expertise should help guide this decision. The accompanying guidelines by the SVS provide details of this process.
This report highlights the need for larger trials to evaluate the relative efficacy of the available treatments for PAD. PAD is a common chronic and disabling condition that deserves appropriate and rigorous evaluation. Trials should follow the comparative effectiveness agenda and needs; thus, they should not include comparisons with placebo or inferior medical management, they should evaluate patient-important outcomes and quality of life, and they should have long-term follow-up. Trials should conceal allocation and blind outcome assessors and seek a high rate of follow-up. Data from registries are also important and can support conclusions from trials as long as registries are protected from selection bias (ie, include complete consecutive cohorts). Cost-effectiveness analysis built alongside these larger trials would be very important for decision-making.
CONCLUSIONS
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